Patents by Inventor Robert F. Mayol

Robert F. Mayol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • S-6-hydroxy-buspirone
    Patent number: 6821976
    Abstract: The S-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The S-isomer may provide reduced potential for adverse effects and a longer duration of action compared to the racemic mixture and with buspirone.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: November 23, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
  • R-6-hydroxy-buspirone
    Patent number: 6686361
    Abstract: The R-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The R-isomer exhibits greater receptor specificity than the S-isomer and should have reduced potential for the adverse effects associated with the racemic mixture and with buspirone.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: February 3, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
  • Antianxiety composition
    Publication number: 20030069251
    Abstract: An improved method of treating anxious patients involves direct administration of 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-piperazinyl]-butyl]-8-azaspiro[4.5]-7,9-dione (BMY 28674) or a pharmaceutically acceptable salt or hydrate formulated in appropriate pharmaceutical compositions to patients in need of such treatment. Syntheses of BMY 28674 are also provided.
    Type: Application
    Filed: July 23, 2002
    Publication date: April 10, 2003
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Edward H. Ruediger
  • R-6-hydroxy-buspirone
    Publication number: 20030055063
    Abstract: The R-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The R-isomer exhibits greater receptor specificity than the S-isomer and should have reduced potential for the adverse effects associated with the racemic mixture and with buspirone.
    Type: Application
    Filed: July 22, 2002
    Publication date: March 20, 2003
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
  • S-6-hydroxy-buspirone
    Publication number: 20030022899
    Abstract: The S-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The S-isomer may provide reduced potential for adverse effects and a longer duration of action compared to the racemic mixture and with buspirone.
    Type: Application
    Filed: July 22, 2002
    Publication date: January 30, 2003
    Inventors: Joseph P. Yevich, Robert F. Mayol, Jianqing Li, Frank Yocca
  • Anxiety method
    Publication number: 20010009913
    Abstract: An improved method of orally dosing buspirone in a manner favoring production of the active metabolite 6-hydroxy-8-[4-[4-(2-pyrimidinyl)-piperazinyl]-butyl]-8-azaspiro[.5]-7,9-dione should enhance the alleviation of anxiety in anxious patients.
    Type: Application
    Filed: March 8, 2001
    Publication date: July 26, 2001
    Inventor: Robert F. Mayol
  • Anxiety method
    Patent number: 6150365
    Abstract: 6-Hydroxy-8-[4-[4-(2-pyrimidinyl)-piperazinyl]-butyl]-8-azaspiro[4.5]-7,9-d ione and its pharmaceutically acceptable salts and hydrates are useful in the alleviation of anxiety.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: November 21, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventor: Robert F. Mayol
  • Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
    Patent number: 5256664
    Abstract: 2-(3-[4-(3-Halophenyl)-1-piperazinyl]propyl derivatives of certain 4-alkyl- or 4-phenoxyalkyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and triazol-3,5-diones are psychotropic agents having promise as antidepressants by virtue of their receptor site binding affinity profiles and animal pharmacology.
    Type: Grant
    Filed: April 28, 1992
    Date of Patent: October 26, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert F. Mayol, George M. Luke
  • Benzanilide derivative
    Patent number: 4618680
    Abstract: 4-Hydroxy-3-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]-phenyl]benzamide is an antiarrhythmic agent having relatively low toxicity and increased duration of action.
    Type: Grant
    Filed: November 27, 1981
    Date of Patent: October 21, 1986
    Assignee: Mead Johnson & Company
    Inventors: Robert F. Mayol, Richard E. Gammans
  • Benzanilide derivative
    Patent number: 4332803
    Abstract: 4-Hydroxy-3-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]-phenyl]benzamide is an antiarrhythmic agent having relatively low toxicity and increased duration of action.
    Type: Grant
    Filed: September 18, 1980
    Date of Patent: June 1, 1982
    Assignee: Mead Johnson & Company
    Inventors: Robert F. Mayol, Richard E. Gammans
  • Encainide assay method
    Patent number: 4318899
    Abstract: A reliable and sensitive immunoassay for encainide in biological fluids including a novel hapten required for antigen synthesis and an immunologically homologous labeled tracer is provided.
    Type: Grant
    Filed: June 2, 1980
    Date of Patent: March 9, 1982
    Assignee: Mead Johnson & Company
    Inventor: Robert F. Mayol